CD163 and cancer: This may be indicative of PD-L1+ cell location is predictive of survival and may reflect stage of cancer, or, when contrasted with the poor survival observed for CD163+ TAMs, is suggestive that stromal PD-L1 and CD163 are expressed on different TAM subsets or that PD-L1 may not be expressed on TAMs at all.